Examples of Supernus Agreement in a sentence
The term of the Supernus Agreement will continue as long as the Topiramate XR and Oxcarbazepine XR products are sold in Canada.
Licensing agreement Pursuant to the terms of the Supernus Agreement, and in addition to the upfront payment of $478,940 (US$350,000), the Company is further obligated to pay an aggregate US$5.15 million in milestone payments upon the achievement of specified regulatory milestones, mid-teen royalty on net sales of Topiramate XR and Oxcarbazepine XR, as well as a milestone payment of US$1.5 million linked to achievement of specified cumulative net sales from both Topiramate XR and Oxcarbazepine XR.
Pursuant to the terms of the Supernus Agreement, and in addition to the upfront payment of $478,940 (US$350,000), the Company is further obligated to pay an aggregate of US$3.6 million in milestone payments upon the achievement of specified regulatory milestones, mid-teen royalty on net sales of Topiramate XR, US$1.5 million on net sales of Oxcarbazepine XR, as well as a milestone payment of US$1.5 million linked to achievement of specified cumulative net sales from both Topiramate XR and Oxcarbazepine XR.
Pursuant to the terms of the Supernus Agreement, the Company paid an upfront fee of $478,940 (US$350,000) and is further obligated to pay additional licensing milestone fees of US$5.15 million, a mid-teen royalty fee on sales and a final sales milestone payment as described in Note 10[b].
Pursuant to the terms of the Supernus Agreement, the Company paid an upfront fee of $478,940 (US$350,000) and is further obligated to pay additional licensing milestone fees of US$5.15 million, a 15% royalty fee on sales and a final sales milestone payment as described in Note 10[c].
Pursuant to the terms of the Supernus Agreement, and in addition to the upfront payment of $478,940 (US$350,000), the Company is further obligated to pay an aggregate US$3.6 million in milestone payments upon the achievement of specified regulatory milestones, mid-teen royalty on net sales of Topiramate XR, US$1.5 million on net sales of Oxcarbazepine XR, as well as a milestone payment of US$1.5 million linked to achievement of specified cumulative net sales from both Topiramate XR and Oxcarbazepine XR.
The license granted to Xxxxxx under Section 2.1 includes a sublicense by Indevus of Indevus’ rights under the Supernus Agreement to the SLI Intellectual Property, solely to use, develop, import, offer for sale, sell, or have sold Product into and throughout the Xxxxxx Territory.
The same can be said for the measures of violence or insecurity, which also figure prominently in the definition.
Xxxxxx acknowledges that it is a sublicensee under the Supernus Agreement to the extent stated in the foregoing sentence and agrees that its rights are limited (and that any sublicensee of Xxxxxx’ rights under this Agreement shall be limited) by the terms and conditions of the Supernus Agreement, to the same extent as Indevus is limited by such terms and conditions, as such terms apply to the sublicense granted to Xxxxxx hereunder, subject to the terms of the Supernus Side Agreement.
TOPIRAMATE XR and OXCARBAZEPINE XR (marketed under the tradenames of Trokendi XR® and Oxtellar XR® in the United States) The third and fourth products in the Company’s commercial pipeline were acquired pursuant to the Supernus Agreement, whereby the Company acquired the Canadian commercial rights to Topiramate XR and Oxcarbazepine XR.